Agilent Technologies, Inc. has revenue of USD 1.19 billion for the fourth-quarter ended October 31, 2017, up 7.1 percent year over year (up 5.8 percent on a core basis(2)).

Fourth-quarter GAAP net income was USD 177 million, or USD 0.54 per share. Last year's fourth-quarter GAAP net income was USD 126 million, or USD 0.38 per share.

During the fourth quarter, Agilent had intangible amortization of USD 28 million, transformation costs of USD 7 million and acquisition and integration costs of USD 5 million. Excluding these items and a tax expense of USD 1 million, Agilent reported fourth-quarter non-GAAP net income of USD 218 million, or USD 0.67 per share(1).

"We ended fiscal 2017 with another strong quarter of revenue and profit growth," said Mike McMullen, Agilent CEO and President. "Every quarter this year we have delivered strong revenue growth, expanded operating margins and increased non-GAAP earnings per share. Our consistently excellent financial performance demonstrates our sustained ability to win in the marketplace, while also driving operational improvements."

"We are successfully executing our strategy positioning Agilent for future growth," he added. "We continue strengthening our portfolio through our own R&D investment and M&A, bringing new capabilities and highly differentiated products to our customers. We have positive momentum heading into fiscal year 2018, and will continue our focus on driving sustainable above-market growth and delivering value to shareholders."

Fourth-quarter revenue of USD 575 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 5 percent year over year (up 4 percent on a core basis(2)), with strength in chemical and energy, academia and government and food end markets. LSAG's operating margin for the quarter was 23.9 percent.

Fourth-quarter revenue of USD 404 million from Agilent CrossLab Group (ACG) grew 9 percent year over year (up 8 percent on a core basis(2)). Growth was healthy across services and consumables, most regions and end markets. ACG's operating margin for the quarter was 22.9 percent.

Fourth-quarter revenue of USD 210 million from Agilent's Diagnostics and Genomics Group (DGG) grew 9 percent year over year (up 7 percent on a core basis(2)) led by increasing demand for pathology products and companion diagnostics services. DGG's operating margin for the quarter was 20.8 percent.

Agilent expects first-quarter 2018 revenue in the range of USD 1.145 billion to USD 1.165 billion. First-quarter 2018 non-GAAP earnings are expected to be in the range of USD 0.55 to USD 0.57 per share.

For fiscal year 2018, Agilent expects revenue of USD 4.720 billion to USD 4.740 billion and non-GAAP earnings of USD 2.50 to USD 2.56 per share. The guidance is based on October 31, 2017, currency exchange rates.  – Medical Buyer Bureau 


A New Cancer Treatment

 

Digital version